Magentiq Eye vs Ultromics EchoGo
A GI group or endoscopy center weighing Magentiq gets vendor-reported figures of 100% polyp-wise sensitivity, 72% frame-wise sensitivity and 97% specificity for standalone detection, and the product page cites no study for them. The company also claims validation in 950+ patients at 10 centers.
Ultromics sells to cardiology and echo labs, where the input is a transthoracic echocardiogram. EchoGo Heart Failure (K240013, September 23, 2024) flags HFpEF from a single apical four-chamber view, and the vendor page quotes sensitivity of 90.3% and specificity of 86.1% from the 510(k). EchoGo Amyloidosis (K240860, November 15, 2024) screens adults 65 and over with heart failure. CPT Category III code 0932T is assigned to the heart failure tool, and the trust page lists HIPAA, ISO 13485:2016 and ISO/IEC 27001:2022.
Radiology · Reviewed November 2, 2026
Magentiq Eye
by MAGENTIQ EYE · founded 2014
Real-time AI polyp detection during colonoscopy, FDA 510(k) cleared as MAGENTIQ-COLO.
Ultromics EchoGo
by Ultromics
FDA-cleared AI on echocardiograms that flags heart failure with preserved ejection fraction and screens for cardiac amyloidosis.
When to pick each one
Magentiq Eye
- Vendor-reported 97% specificity, no study cited
- Polyp detection during colonoscopy
- Validation claim of 950+ patients at 10 centers
Ultromics EchoGo
- HFpEF flag from one apical four-chamber echo view
- Amyloidosis screening for adults 65 and over
- Trust page lists HIPAA and ISO/IEC 27001:2022
Score
Each row shows points earned of points available under the published rubric.
Magentiq Eye
35of 100
Ultromics EchoGo
42of 100
| Dimension | Magentiq Eye | Ultromics EchoGo | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 6 / 10 | -6 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 0 / 18.2 | 0 / 18.2 | 0 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 3 / 12 | 8.4 / 12 | -5.4 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
Magentiq Eye
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Monthly rental stated. |
Ultromics EchoGo
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
Magentiq Eye
FDA decisions
K260724 (opens in new tab)510(k)2026-04-03
MAGENTIQ-COLO (ME-APDS)
K252178 (opens in new tab)510(k)2025-10-03
MAGENTIQ-COLO (ME-APDS)
K244023 (opens in new tab)510(k)2025-01-24
MAGENTIQ-COLO (ME-APDS)
K223473 (opens in new tab)510(k)2023-07-25
ME-APDS; MAGENTIQ-COLO
Ultromics EchoGo
FDA decisions
K240860 (opens in new tab)510(k)2024-11-15
EchoGo Amyloidosis (1.0)
K240013 (opens in new tab)510(k)2024-09-23
EchoGo Heart Failure (2.0)
K222463 (opens in new tab)510(k)2022-11-23
EchoGo Heart Failure 1.0
K213275 (opens in new tab)510(k)2021-12-20
EchoGo Core (2.0)
K201555 (opens in new tab)510(k)2020-12-18
EchoGo Pro v1.0.2
Show 1 more
K191171 (opens in new tab)510(k)2019-11-13
EchoGo Core
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Magentiq Eye | Ultromics EchoGo |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2014 | n/a |
| HQ | IL | GB |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.